Treprostinil (Tyvaso®)

Status
To Patients
Condition
Pulmonary Hypertension
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. 

More Information

TYVASO.com 

 

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >